Home › Lung Cancer › NCT06482073

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (INTERCEPTioN for Suspected Lung Cancer)for Suspected Lung Cancer)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Subject age 18 years and older
* Subject is scheduled/was scheduled for a bronchoscopy or surgical resection as part of standard of care
* Subject with a moderate to high risk of lung cancer based on clinical demographic and radiologic information or with suspected metastatic disease
* Ability to provide blood or saliva sample
* Ability to provide archived tissue
* Subject is able to understand and adhere to study requirements and able to provide informed consent

Exclusion Criteria:

* Individuals who have situations that would limit compliance with the study requirements
* Institutionalized (i.e. federal medical prison)
* Pregnant
* Prior germline genetic testing with a 40+ multi-gene panel AND/OR prior somatic tissue (250+ gene) testing utilizing the tissue from the bronchoscopy or surgical resection

About the study

This study evaluates the effectiveness of tumor samples in providing information about hereditary or cancer specific genetic variants that may have a role in diagnosis of cancer and to develop genetic results and medical record databank for future studies.

What is being tested

• Non-Interventional Study (other)

Sponsor: Mayo Clinic · Participants: 250 · Started: Jun 24, 2024

Contact the study team

• Thoracic Research · Phone: 507-293-0807

Official record on ClinicalTrials.gov — NCT06482073

Locations in the U.S.

Conditions

• Lung Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.